Zoptarelin Doxorubicin

Roughly 80 percent of endometrial and ovarian cancers, and a large fraction of prostate cancers, express LHRH receptors on the tumour cell surface — a target that healthy tissue outside the pituitary and gonads largely lacks. Zoptarelin doxorubicin exploits that by attaching doxorubicin through a glutaric acid ester to the side chain of D-lysine at position 6 of an LHRH agonist analogue. The conjugate binds the receptor, is internalised by endocytosis, and lysosomal enzymes cleave the linker to liberate doxorubicin and doxorubicinol inside the cell, where they intercalate DNA and poison topoisomerase II. The intended payoff was doxorubicin's efficacy without its cumulative cardiotoxicity, because far less free drug reaches the myocardium. Cardiac sparing was in fact observed; unfortunately, so was equivalent efficacy to plain doxorubicin.

Targets: LHRH / GnRH receptor on tumour cells, Topoisomerase II and DNA (via the released doxorubicin payload)

• · 267 mg/m2 per cycle, chosen as doxorubicin-equivalent exposure. This regimen exists only in the trial record — the drug was never marketed.

Work out your exact syringe units →

• very commonNeutropenia— The dominant toxicity in trial, as with the parent anthracycline.
• very commonAnaemia and thrombocytopenia
• very commonNausea, vomiting and mucositis
• very commonAlopecia— Occurred despite the targeting, confirming meaningful free-drug exposure.
• very commonFatigue
• uncommonCardiotoxicity— Notably less than expected for equivalent doxorubicin exposure — the one part of the design that demonstrably worked.

• Not applicable in practice — the drug is not available. In trial, standard anthracycline exclusions applied, including significant cardiac dysfunction and prior maximal anthracycline exposure.
• Pregnancy — cytotoxic and genotoxic.

• conflictGnRH agonists and antagonists — Competing for the same LHRH receptor would be expected to blunt tumour uptake of the conjugate.
• cautionOther anthracyclines — Cumulative cardiac dose counts across the whole class.

• · Full blood count before each cycle.
• · Left ventricular ejection fraction by echocardiogram or MUGA, as for any anthracycline.
• · Tumour response by cross-sectional imaging every 2 to 3 cycles.

Never approved anywhere. Development discontinued after the phase 3 readout in 2017; not obtainable outside archived trial supply.

• ZoptEC phase 3 trial of zoptarelin doxorubicin versus doxorubicin in advanced endometrial cancer, reported 2017 (trial)
• Reviews of LHRH-receptor-targeted cytotoxic peptide conjugates (AN-152 / AEZS-108) in gynaecological oncology (review)

The premise was sound and the arithmetic looked compelling. Roughly 80 percent of endometrial and ovarian cancers, and a large fraction of prostate and breast cancers, express LHRH receptors on the tumour cell surface. Outside the pituitary gonadotroph and the gonads, healthy tissue largely does not — and critically, cardiac myocytes do not. So attaching doxorubicin to an LHRH analogue should deliver anthracycline into the tumour and spare the heart, which is the dose-limiting organ for the entire anthracycline class. The conjugate binds the tumour LHRH receptor, is internalised by receptor-mediated endocytosis, and lysosomal esterases cleave the glutaric acid linker to liberate doxorubicin and its metabolite doxorubicinol inside the cell, where they intercalate DNA and poison topoisomerase II, generating double-strand breaks. Cardiac sparing was in fact demonstrated — this is the part of the design that worked, and the trials confirmed it. What did not follow was efficacy. In the phase 3 ZoptEC trial, median overall survival was close to 11 months in both the conjugate and the plain doxorubicin arms. Several explanations compete and none is settled. The linker may hydrolyse too readily in circulation, so a substantial fraction of the payload is simply free doxorubicin by the time it reaches the tumour — the persistence of alopecia and neutropenia at ordinary anthracycline rates is consistent with that. Receptor density on tumour cells may be too low to deliver a meaningful drug load per cell, since a receptor delivers one payload molecule per internalisation event and doxorubicin is not a potent enough cytotoxin for that arithmetic to work, which is precisely why modern antibody-drug conjugates use payloads a thousand times more potent. And LHRH receptor expression, while common, is heterogeneous within tumours. The clean lesson is that reduced toxicity without improved efficacy does not carry a registration, and that payload potency, not targeting elegance, is the binding constraint on conjugate design.

Everything about this record is a post-mortem. The mechanism was elegant, the cardiac sparing was real and measurable, alopecia and neutropenia occurred at ordinary anthracycline rates — which quietly told everyone that meaningful free doxorubicin was circulating — and the phase 3 showed no survival difference at all, roughly 11 months in both arms. Development stopped in 2017. Three lessons are worth carrying out of it. First, payload potency is the binding constraint in conjugate design: a receptor delivers a limited number of payload molecules per cell, and doxorubicin is simply not potent enough for that arithmetic, which is why every successful modern antibody-drug conjugate uses a payload one to three orders of magnitude more cytotoxic. Second, linker stability in circulation determines whether you have a targeted drug or a slow-release prodrug of the free cytotoxin, and an ester linker in plasma is an optimistic choice. Third, and most importantly for how anyone should read oncology news: reduced toxicity without improved efficacy does not get a drug approved and should not. A safer version of a drug that does not work better is not a better drug.

1. —Every 21 days, up to 9 cycles — 267 mg/m2 per cycle infused over about 2 hours, chosen as doxorubicin-equivalent molar exposure. Body-surface-area dosed. The cycle cap existed to limit cumulative anthracycline exposure. This regimen exists only in the trial record — the drug was never marketed.

• LHRH / GnRH receptor on tumour cells — Retains LHRH agonist binding; specific affinity constants for the conjugate are not established in accessible published data

  Receptor-mediated endocytosis of the whole conjugate, delivering doxorubicin into the tumour cell interior. Expressed by roughly 80 percent of endometrial and ovarian cancers.

• Topoisomerase II, via the released doxorubicin payload

  Traps the cleavage complex, producing double-strand breaks and apoptosis. Standard anthracycline mechanism once the payload is free.

• Genomic DNA, by intercalation

  Distorts the helix and blocks replication and transcription.

• Cardiac myocytes — deliberately not targeted — LHRH receptor is essentially absent from myocardium

  The intended advantage, and the one part of the design that demonstrably delivered. Cardiotoxicity was notably lower than expected for equivalent doxorubicin exposure.

• ZoptEC (NCT01767155) Phase 3 · n=511 · 2017

  Overall survival with zoptarelin doxorubicin versus doxorubicin monotherapy as second-line therapy for advanced or recurrent endometrial cancer. No survival advantage — median survival was close to 11 months in both arms. Trial completed January 2017 and development was discontinued.

• Phase 2 of AEZS-108 in castration- and taxane-resistant prostate cancer Phase 2 · 2017

  Response and tolerability in LHRH-receptor-expressing castration-resistant prostate cancer. Part of the wider development programme that also covered ovarian and bladder cancer.

Historical only. In trial, the conjugate was infused over about 2 hours every 21 days and tumour response was assessed radiographically after 2 to 3 cycles, so 6 to 9 weeks. Neutrophil nadir followed the standard anthracycline pattern at roughly days 10 to 14. Alopecia appeared over the first two cycles. Cardiac effects, where they occurred, were late and cumulative as with any anthracycline.

There is nothing to stack, because there is no drug. In trial it was given as monotherapy against doxorubicin monotherapy. The mechanistically obvious conflict is with GnRH agonists and antagonists, which compete for the same LHRH receptor and would be expected to block tumour uptake of the conjugate entirely — an important consideration in prostate cancer, where almost every patient is already on androgen deprivation acting at exactly that receptor. Whether that competition contributed to the disappointing prostate results is an open question. The other constraint is anthracycline arithmetic: cumulative cardiac dose counts across the whole class and across a lifetime, so prior doxorubicin or epirubicin exposure limits how much of any anthracycline, targeted or not, a patient can receive. The conjugate's cardiac sparing did not exempt it from that ceiling in trial design, and it is worth noting that the sparing was demonstrated but never given the chance to translate into a higher lifetime dose.

Against plain doxorubicin, the phase 3 answer is that survival was the same and cardiotoxicity was lower. That is a real result, just not a registrable one. Against melphalan flufenamide, the other peptide-drug conjugate in this class, the pattern repeats with unsettling precision: a clever delivery mechanism that provably did what it was designed to do at the molecular level, and no survival benefit to show for it. Against modern antibody-drug conjugates such as trastuzumab deruxtecan or sacituzumab govitecan, the contrast is instructive and explains the failure — those use payloads far more cytotoxic than doxorubicin, linkers engineered for plasma stability with controlled intracellular release, and targets with much higher surface density, plus a bystander effect that reaches antigen-negative neighbouring cells. Zoptarelin doxorubicin had none of those four properties. Against the LHRH-targeting concept in general, the hypothesis has not been abandoned — newer LHRH conjugates with more potent payloads are in preclinical development — and it may yet work with better chemistry. This molecule is the cautionary first draft.

Not applicable. Never approved and never marketed anywhere. Development was discontinued in 2017 and no commercial supply has ever existed.

• ?The amino acid sequence is set unverified. The [D-Lys6]-LHRH backbone with a glutaryl-doxorubicin conjugate at position 6 is reported consistently across the literature, but I did not resolve a primary structural source in this session.
• ?Molecular weight is left null, as in the Core record, because published values for the conjugate are inconsistent.
• ?Volume of distribution, clearance and protein binding are not established in accessible human data. The PBPK model provides a simulated description rather than measured parameters.
• ?The tmax of 2 hours is inferred from the end of a 2-hour infusion, not a separately reported parameter.
• ?The primary ZoptEC publication was not resolved. Trial existence, phase, enrolment of 511, primary endpoint and January 2017 completion were verified through the ClinicalTrials.gov registry record, and the survival figures come from the Core record's account rather than from a paper I read.
• ?The Yu 2017 prostate phase 2 enrolment is left null because I resolved the publication record but not the participant count.
• ?Why the drug failed is not established. Premature linker hydrolysis, insufficient payload potency, low receptor density and intratumoral heterogeneity are all plausible and none has been demonstrated to be decisive.
• ?LHRH receptor expression was never validated as a selection biomarker with a defined assay or cut-off, which limits what can be concluded from the negative result.

• Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer (NCT01767155) Aeterna Zentaris, ClinicalTrials.gov registry record, 2017

  Registry record confirming ZoptEC as a completed phase 3 with 511 participants and overall survival as its primary endpoint, comparing the conjugate against doxorubicin monotherapy. Completion January 2017.

• A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin Hanke N, Frechen S, Moj D, et al., Cancer Chemotherapy and Pharmacology, 2018 · PMID 29204687

  The only serious quantitative description of this conjugate's disposition and of the released doxorubicin, and the reason there is any pharmacokinetic content in this record at all.

• A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer Yu SS, Athreya K, Liu SV, et al., Clinical Genitourinary Cancer, 2017 · PMID 28668277

  Shows the breadth of the development programme beyond endometrial cancer, and that the LHRH-targeting hypothesis was tested in more than one receptor-positive tumour.